Moderna surges after late-stage melanoma vaccine results
Moderna (MRNA) is up more than 90% this morning following an experimental cancer vaccine jointly developed with Merck that showed promise in a late-stage melanoma trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.